Duchenne muscular dystrophy was nominated to be added to the Recommended Uniform Screening Panel (RUSP), a list of disorders that are screened for at birth. This is an important step […]
Happy Father’s Day to all of the dads out there who have either found a way – or made one – so that their kids can experience their best life.
– Paul Miller, aka Hawken’s dad
Enjoy this hand-picked selection of books about Duchenne muscular dystrophy for children and parents. This list was shared at the 2022 FUTURES National Conference in Orlando, FL. (Duchenne Community Bookstore […]
We’re thrilled to share news about Code Biotherapeutics, a company pioneering targeted non-viral delivery of genetic medicines. CureDuchenne’s April 2021 research investment into Code Biotherapeutics was based on extensive preclinical […]
The 2021 National Organization for Rare Disorders (NORD) Breakthrough Summit saw a number of innovations unveiled for the rare disease community. RareDisease Advisor was there to cover the highlights of […]
CureDuchenne joins forces with NIH, FDA, and private organizations to increase effective gene therapies for rare diseases CureDuchenne is delighted to be a partner in the Accelerating Medicines Partnership Bespoke […]
In WMS 2021’s final day and “late-breaking news” session, Capricor Therapeutics announced positive final data from its Phase 2 HOPE-2 clinical trial in Duchenne patients treated with CAP-1002. HOPE-2 was […]
WMS 2021 on Thursday, September 23rd was a full day of oral and poster presentations, and we’ll highlight some Duchenne clinical trial updates covered. Solid Biosciences – SGT-001 micro-dystrophin gene […]
WMS 2021’s agenda on Wednesday, September 22nd was not so much about specific diseases, but rather major and timely research themes across all of biology. The day started with a […]
